Comment on Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. Vaccines 2026, 14, 411
- DOI
- 10.3390/vaccines14090758
- Published
- 2026-08-31
- Container
- Vaccines
- Publisher
- MDPI AG
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3390/vaccines14090758,
title = {Comment on Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. Vaccines 2026, 14, 411},
author = {Erin N. Hodges and Mehdi Ghemmouri and Maureen P. Neary and Veronica Gabriel and Cecilia Ottaviano and Karine Mari and Veronica Ottobrino and Ayman Chit and Joseph Domachowske and Benjamin Yarnoff and Robert Musci and Leonard R. Krilov},
year = {2026},
journal = {Vaccines},
doi = {10.3390/vaccines14090758},
url = {https://doi.org/10.3390/vaccines14090758}
}RIS
TY - JOUR TI - Comment on Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. Vaccines 2026, 14, 411 AU - Erin N. Hodges AU - Mehdi Ghemmouri AU - Maureen P. Neary AU - Veronica Gabriel AU - Cecilia Ottaviano AU - Karine Mari AU - Veronica Ottobrino AU - Ayman Chit AU - Joseph Domachowske AU - Benjamin Yarnoff AU - Robert Musci AU - Leonard R. Krilov PY - 2026 JO - Vaccines DO - 10.3390/vaccines14090758 UR - https://doi.org/10.3390/vaccines14090758 ER -
APA
Hodges, E. N., Ghemmouri, M., Neary, M. P., Gabriel, V., Ottaviano, C., Mari, K., Ottobrino, V., Chit, A., Domachowske, J., Yarnoff, B., Musci, R., & Krilov, L. R. (2026). Comment on Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. Vaccines 2026, 14, 411. Vaccines. https://doi.org/10.3390/vaccines14090758
Source records
- crossref · retrieved 2026-09-26T16:45:31.436Z